Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
Ragnoli B, Morjaria J, Pignatti P, Montuschi P, Barbieri M, Mondini L, Ruggero L, Trotta L, Malerba M.
Ragnoli B, et al. Among authors: malerba m.
Ther Adv Chronic Dis. 2022 May 25;13:20406223221097327. doi: 10.1177/20406223221097327. eCollection 2022.
Ther Adv Chronic Dis. 2022.
PMID: 35655942
Free PMC article.
Review.